ASCO 2026 is over. Here’s what it means for your pipeline and your portfolio.
The 2026 ASCO Annual Meeting brought a wave of new oncology data, from bladder cancer ADCs to next-generation breast and lung cancer therapies. Sorting through hundreds of abstracts and presentations takes time most teams don’t have.
Our Post-ASCO Report breaks down the data that matters, drug by drug and indication by indication, with analyst commentary on what it means clinically and commercially.
This report covers every major data event added to Biomedtracker around the meeting. You get the trial design, the results, and our take on likelihood of approval, competitive positioning, and commercial impact. No abstract scanning required.
What’s inside
The report covers data across more than 40 cancer types and indications, including bladder cancer, breast cancer, colorectal cancer, gastric cancer, lung cancer, multiple myeloma, ovarian cancer, prostate cancer, and more. Each entry includes trial design and results alongside Biomedtracker’s clinical and commercial analysis.
